Libroxar

Buprenorphine/Naloxone, the active ingredient in Libroxar, is a partial opioid agonist / opioid antagonist combination presented as a sublingual formulation for sublingual use. It is indicated for the treatment of opioid dependence and opioid use disorder in adults. GNH USA supplies Libroxar as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Libroxar is a partial opioid agonist/antagonist used in the management of opioid‑related disorders. - Opioid dependence: reduces cravings and eases withdrawal symptoms. - Opioid use disorder: stabilises opioid receptors to support recovery. - Maintenance therapy for opioid dependence: provides long‑term control of opioid cravings and prevents relapse.

Adverse reactions may occur with Libroxar and are reported in clinical use.

Common Side Effects: - Nausea: mild to moderate upset stomach. - Constipation: reduced bowel movements. - Headache: transient cranial discomfort. - Sweating: increased perspiration, especially at night. - Insomnia: difficulty falling or staying asleep. - Dry mouth: reduced salivation.

Serious or Rare Side Effects: - Respiratory depression: slowed breathing, potentially life‑threatening. - Severe hypotension: marked drop in blood pressure. - Hepatic dysfunction: abnormal liver enzymes or jaundice. - QT interval prolongation: cardiac rhythm disturbance. - Allergic reactions: rash, angioedema, or anaphylaxis. - Seizures: rare convulsive episodes.

Libroxar requires careful clinical monitoring to ensure safety. - Assess liver function: evaluate hepatic status before initiation. - Monitor respiratory status: watch for signs of depression, especially with other depressants. - Avoid use in acute intoxication: do not start treatment during active opioid overdose. - Use caution with CNS depressants: adjust therapy when combined with benzodiazepines or alcohol. - Store at ambient temperature: keep in the original pack, protect from moisture.

Libroxar can interact with several drug classes, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Benzodiazepines: increased risk of respiratory depression. - Other opioids: additive opioid effects may cause profound sedation. - Alcohol: potentiates central nervous system depression.

Moderate Interactions (Monitor Closely): - SSRIs and SNRIs: may enhance serotonergic effects. - Antihypertensives: possible additive hypotensive effect. - Rifampin: may reduce buprenorphine plasma levels.